Undoctored vault view

Approval for pholcodine (a medicine found in some cough syrups and lozenges) to be sold in New Zealand will be withdrawn on 12 January 2024.

Te Pātaka Whaioranga – Pharmac is widening access to COVID-19 antivirals to people who are vulnerable to severe infection from COVID-19, including those with disabilities and with one or more severe health conditions

While the new vaping laws are a step in the right direction, Government's efforts continue to fall short in addressing the escalating vaping crisis among our youth

Te Whatu Ora is continuing efforts to try to reach a settlement with the Association of Salaried Medical Specialists (ASMS)

A person in Tāmaki Makaurau has been confirmed with measles after recent overseas travel.

A public hearing on the Environmental Protection Authority’s (EPA) proposed updates to the Cosmetic Products Group Standard, which contains rules for cosmetics in Aotearoa New Zealand, will be held on Wednesday 20 September 2023

Te Whatu Ora is extremely disappointed the Association of Salaried Medical Specialists (ASMS) is indicating further industrial action by senior doctors and dentists, without letting their members know the details of the current pay offer.

A new cervical screening test, available from today, is expected to increase screening rates and significantly reduce cervical cancer deaths in Aotearoa New Zealand.

Auckland based Douglas Pharmaceuticals has signed a license agreement with U.S based Daré Bioscience, Inc to develop and commercialise R-131-2, a novel topical medicinal candidate for the treatment for cervical intraepithelial neoplasia.

Te Pātaka Whaioranga – Pharmac has confirmed supply agreements for a range of funded vaccines including those that protect against influenza and meningococcal disease. This follows a request for proposals (RFP) competitive process